z-logo
Premium
Efficacy of telbivudine treatment for hepatitis B e antigen‐positive chronic hepatitis B patients with poor response to adefovir dipivoxil
Author(s) -
Li Y.,
Zhang Y.,
Wang J.P.,
Lian J.Q.,
Bai X.F.
Publication year - 2013
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12063
Subject(s) - telbivudine , adefovir , medicine , seroconversion , hbeag , chronic hepatitis , hepatitis b , adverse effect , gastroenterology , viral load , virology , hepatitis b virus , immunology , lamivudine , virus , hbsag
Summary Telbivudine ( LdT ) has demonstrated potent antiviral activity in nucleos(t)ide analogue ( NA )‐naïve chronic hepatitis B patients ( CHB ), but data on its efficacy in NA ‐experienced patients are limited. The aim of this study was to investigate the effect of LdT in hepatitis B e antigen‐positive CHB patients with poor response to initial adefovir dipivoxil ( ADV ). Forty‐two CHB patients with HBV DNA > 4 log 10  copies/mL after 12 months of ADV monotherapy were enroled in the study and thereafter treated with LdT 600 mg daily for 18 months. Telbivudine led to a rapid decrease in viral load, and viral replication was persistently suppressed with a reduction of 2.26 log 10  copies/mL 18 months after LdT treatment. The rates corresponding to virological and biochemical response at the end of observation were 97.6% (41/42) and 65.8% (25/38), respectively. HBeAg loss was found in 30.8% (12/39) of patients, while HB e A g/anti‐ HB e seroconversion was found in 17.9% (7/39). Only one patient was detected to have LdT ‐associated mutation, and no severe adverse events were reported. Optimization therapy with LdT monotherapy may be a good choice for CHB patients with poor response to ADV , and switching to LdT may be the most cost‐effective rescue therapeutic strategy for patients with poor response to initial ADV monotherapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here